Abstract:SMAD4 is a well-characterized tumor suppressor gene frequently inactivated in pancreatic adenocarcinoma (PDAC). Loss of SMAD4-mediated epithelial cell growth inhibition contributes to stromal cell-mediated tumor invasion and metastases. Loss of SMAD4 has been identified as a prognosticator of worse clinical outcome and metastatic failure. We attempt to correlate methylation patterns with changes in gene expression of SMAD4 characterized patient derived xenografts (PDX), and identify profiles that may predict response to radiation. With IACUC approval, 20 PDAC PDXs characterized for KRAS, p53 and SMAD4 were implanted into bilateral flanks of mice and irradiated. Left flank tumors received 5 Gy/day for 2 days using the right flank as a control (n = 5 per group). Tumor dimensions were obtained twice weekly (volume = (LxW2)/2); tumor growth inhibition (TGI) was calculated (treated tumor volume/control tumor volume). Gene expression data (Affymetrix GeneChip) was preprocessed with quantile normalization and log2 transformation. Methylation microarrays (Illumina 450k) were processed with quantile normalization, beta-value scale, and M-value. Key pathways of differentially expressed genes were investigated with KEGG pathway enrichment analysis. Comparison of SMAD4 mutant (n = 10) and intact (n = 10) tumors revealed 621 and 602 differentially expressed genes following gene expression and methylation array analysis, respectively. Prominent KEGG pathways included endocytosis, melanogenesis, tight junction, ascorbate and aldarate metabolism, steroid hormone biosynthesis, and androgen and estrogen metabolism. Three genes with the strongest inverse correlation between levels of methylation and mRNA expression included ACOX2 (r = -.56, p = .01), CTAGE5 (r = -.7, p = .0004), and LY75 (r = .61, p = .004). Gene expression and methylation analysis as a function of relative TGI revealed 301 and 447 differentially expressed genes, respectively, and these were enriched in the pathways in cancer, melanoma, and aldosterone-regulated sodium reabsorption pathways. Irradiated tumors revealed a varying range of TGI (-58% to +72%). Using univariate linear regression to correlate TGI with gene expression and methylation revealed 5 target genes (C6orf125, CFD, DNAI1, GLI3, and TRIM24) with strong inverse correlation (r = .53-.61, p<.02). Correlation of gene expression with methylation profiles of SMAD4-characterized PDAC revealed gene signatures suggestive of metabolic and hormonal dysregulation, which may contribute to the aggressive nature of SMAD4-mutant tumors. Further investigation is underway to identify potential molecular drug targets, and a signature to predict response to RT and patterns of failure.

SMAD4 Limits PARP1 dependent DNA Repair to Render Pancreatic Cancer Cells Sensitive to Radiotherapy

Data from <i>smad4</i> Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy Through Promotion of Autophagy

Synergistic Antitumor Efficacy of Rmv-Hu191 and Olaparib in Pancreatic Cancer by Generating Oxidative DNA Damage and ROS-dependent Apoptosis

Figure S1 from <i>smad4</i> Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy Through Promotion of Autophagy

Correlation of Methylation Patterns and Gene Expression with Radiation Response of SMAD4-Characterized Pancreatic Cancer Xenografts

SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer

Smad4 Deficiency Promotes Pancreatic Cancer Immunogenicity by Activating the Cancer‐Autonomous DNA‐Sensing Signaling Axis

Perspectives on the Combination of Radiotherapy and Targeted Therapy with DNA Repair Inhibitors in the Treatment of Pancreatic Cancer.

SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy

DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer

PARP inhibitors diminish DNA damage repair for the enhancement of tumor photodynamic therapy.

PARP1 controls the transcription of CD24 by ADP-ribosylating the RNA helicase DDX5 in pancreatic cancer

NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy

SMAD4 and Its Role in Pancreatic Cancer

Synergistic Action of Smad4 and Pten in Suppressing Pancreatic Ductal Adenocarcinoma Formation in Mice

KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid accumulation in pancreatic ductal adenocarcinoma

Identification of Key Genes Mutations Associated With the Radiosensitivity by Whole Exome Sequencing in Pancreatic Cancer

BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy

P53 Deficiency-Induced Smad1 Upregulation Suppresses Tumorigenesis and Causes Chemoresistance in Colorectal Cancers.

An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies